secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001104659-24-060517
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics submits UK MAA for ONS-5010 (bevacizumab gamma) for wet AMD
--------------------------------------------------------------------------------

- Submitted MAA to UK MHRA via International Recognition Procedure, relying on March 2024 positive CHMP opinion.
- ONS-5010 is proposed as the first on-label ophthalmic bevacizumab for wet AMD in the UK.
- Clinical program support from three completed registration trials: NORSE ONE, TWO, and THREE.
- EU decision on CHMP opinion expected within ~67 days; applies to 27 Member States plus Iceland, Norway, Liechtenstein.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924060517/0001104659-24-060517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924060517/tm2414311d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer